Cassava Sciences Inc (SAVA)
28.48
-3.38
(-10.62%)
USD |
NASDAQ |
Sep 27, 16:00
28.47
-0.02
(-0.05%)
After-Hours: 20:00
Cassava Sciences Research and Development Expense (Annual): 89.42M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 89.42M |
| December 31, 2022 | 68.03M |
| December 31, 2021 | 24.81M |
| December 31, 2020 | 3.053M |
| December 31, 2019 | 1.568M |
| December 31, 2018 | 2.969M |
| December 31, 2017 | 7.615M |
| December 31, 2016 | 9.176M |
| December 31, 2015 | 9.10M |
| December 31, 2014 | 7.306M |
| December 31, 2013 | 4.917M |
| December 31, 2012 | 7.605M |
| December 31, 2011 | 8.30M |
| Date | Value |
|---|---|
| December 31, 2010 | 15.75M |
| December 31, 2009 | 21.06M |
| December 31, 2008 | 45.82M |
| December 31, 2007 | 47.73M |
| December 31, 2006 | 46.80M |
| December 31, 2005 | 32.94M |
| December 31, 2004 | 35.09M |
| December 31, 2003 | 18.91M |
| December 31, 2002 | 11.40M |
| December 31, 2001 | 11.67M |
| December 31, 2000 | 12.60M |
| December 31, 1999 | 2.092M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
1.568M
Minimum
2019
89.42M
Maximum
2023
37.38M
Average
24.81M
Median
2021
Research and Development Expense (Annual) Benchmarks
| Bristol-Myers Squibb Co | 9.299B |
| Eli Lilly and Co | 9.313B |
| Seelos Therapeutics Inc | 30.12M |
| Moderna Inc | 4.845B |
| Biomarin Pharmaceutical Inc | 746.77M |